Allergy Therapeutics's total assets for Q4 2025 were £67.54M, a decrease of -7.44% from the previous quarter. GB:AGY total liabilities were £95.74M for the fiscal quarter, a 19.49% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.